{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:41:28Z","timestamp":1784151688818,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016372","name":"Desitin Arzneimittel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.yebeh.2020.107139","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T08:11:26Z","timestamp":1589530286000},"page":"107139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Treatment of status epilepticus with zonisamide: A multicenter cohort study of 34 patients and review of literature"],"prefix":"10.1016","volume":"109","author":[{"given":"Kristina","family":"Hubert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Knake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2020.107139_bb0005","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","article-title":"Status epilepticus in adults","volume":"14","author":"Betjemann","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2020.107139_bb0010","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/epi.13837","article-title":"Costs, length of stay, and mortality of super-refractory status epilepticus: a population-based study from Germany","volume":"58","author":"Strzelczyk","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107139_bb0015","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/epi.14729","article-title":"Burden and epidemiology of status epilepticus in infants, children, and adolescents: a population-based study on German health insurance data","volume":"60","author":"Schubert-Bast","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107139_bb0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ana.25416","article-title":"Factors predicting cessation of status epilepticus in clinical practice: data from a prospective observational registry (SENSE)","volume":"85","author":"Kellinghaus","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2020.107139_bb0025","article-title":"Epidemiology of status epilepticus in adults: apples, pears, and oranges \u2014 a critical review","volume":"106720","author":"Leitinger","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107139_bb0030","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1093\/brain\/awr215","article-title":"The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol","volume":"134","author":"Shorvon","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2020.107139_bb0035","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.yebeh.2015.04.010","article-title":"Preliminary results of the global audit of treatment of refractory status epilepticus","volume":"49","author":"Ferlisi","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107139_bb0040","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/brain\/aws091","article-title":"The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy","volume":"135","author":"Ferlisi","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2020.107139_bb0045","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0920-1211(01)00282-0","article-title":"Long-term observations of two siblings with Lafora disease treated with zonisamide","volume":"46","author":"Yoshimura","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.107139_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejpn.2007.05.003","article-title":"Long-term use of zonisamide in refractory childhood-onset epilepsy","volume":"12","author":"Kluger","year":"2008","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2020.107139_bb0055","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.seizure.2013.03.007","article-title":"Intravenous initiation and maintenance of ketogenic diet: proof of concept in super-refractory status epilepticus","volume":"22","author":"Strzelczyk","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107139_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-328X(03)00183-9","article-title":"Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures","volume":"116","author":"Ueda","year":"2003","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.yebeh.2020.107139_bb0065","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s11064-005-7586-9","article-title":"In vivo evaluation of the effect of zonisamide on the hippocampal redox state during kainic acid-induced seizure status in rats","volume":"30","author":"Ueda","year":"2005","journal-title":"Neurochem Res"},{"key":"10.1016\/j.yebeh.2020.107139_bb0070","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s10787-018-0478-9","article-title":"A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures","volume":"26","author":"Kumar","year":"2018","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.yebeh.2020.107139_bb0075","first-page":"1288","article-title":"Bioavailability of zonisamide capsule administered as sprinkle in healthy subjects","volume":"21","author":"Shah","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.yebeh.2020.107139_bb0080","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2146\/ajhp080250","article-title":"Stability of zonisamide in extemporaneously compounded oral suspensions","volume":"66","author":"Abobo","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.yebeh.2020.107139_bb0085","series-title":"A clinical guide","first-page":"145","article-title":"Zonisamide antiepileptic drug interactions","author":"Patsalos","year":"2016"},{"key":"10.1016\/j.yebeh.2020.107139_bb0090","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1046\/j.1528-1157.2001.01101.x","article-title":"Incidence of status epilepticus in adults in Germany: a prospective, population-based study","volume":"42","author":"Knake","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107139_bb0095","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/epi.13584","article-title":"Costs and cost-driving factors for acute treatment of adults with status epilepticus: a multicenter cohort study from Germany","volume":"57","author":"Kortland","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107139_bb0100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fneur.2017.00507","article-title":"Socioeconomic outcome and quality of life in adults after status epilepticus: a multicenter, longitudinal matched case\u2013control analysis from Germany","volume":"8","author":"Kortland","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2020.107139_bb0105","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2020.107139_bb0110","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107139_bb0115","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107139_bb0120","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus \u2014 report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107139_bb0125","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00415-008-0989-1","article-title":"Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy","volume":"255","author":"Rossetti","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2020.107139_bb0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/phar.2229","article-title":"Use of newer anticonvulsants for the treatment of status epilepticus","volume":"39","author":"Farrokh","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.yebeh.2020.107139_bb0135","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/14656566.2019.1595584","article-title":"An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy","volume":"20","author":"Reimers","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2020.107139_bb0140","first-page":"218","article-title":"Zonisamide is effective in the treatment of myoclonus status epilepticus and myoclonus in Jokob\u2013Creutzfeldt disease (Abstract 2.259)","volume":"43","author":"Ganguly","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107139_bb0145","first-page":"50","article-title":"Symptomatic nonconvulsive status epilepticus controlled after oral treatment with zonisamide and levetiracetam (Abstract p162)","volume":"51","author":"Lazzaro","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107139_bb0150","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/epi.16382","article-title":"Treatment of refractory and superrefractory status epilepticus with topiramate: a cohort study of 106 patients and a review of the literature","volume":"60","author":"Fechner","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107139_bb0155","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/11633090-000000000-00000","article-title":"Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study","volume":"26","author":"Hottinger","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2020.107139_bb0160","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.eplepsyres.2011.09.017","article-title":"The efficacy of topiramate in adult refractory status epilepticus: experience of a tertiary care center","volume":"98","author":"Synowiec","year":"2012","journal-title":"Epilepsy Res"},{"issue":"Suppl. 2","key":"10.1016\/j.yebeh.2020.107139_bb0165","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/epi.14494","article-title":"Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit: a single-center audit of 30 patients","volume":"59","author":"Rohracher","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107139_bb0170","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/ane.13061","article-title":"Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain","volume":"139","author":"Strzelczyk","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2020.107139_bb0175","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.seizure.2013.11.002","article-title":"Use of oxcarbazepine for treatment of refractory status epilepticus","volume":"23","author":"Kellinghaus","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107139_bb0180","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ane.12403","article-title":"Stiripentol for the treatment of super-refractory status epilepticus","volume":"132","author":"Strzelczyk","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2020.107139_bb0185","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/ane.12888","article-title":"Stiripentol for the treatment of super-refractory status epilepticus with cross-sensitivity","volume":"137","author":"Uchida","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2020.107139_bb0190","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.yebeh.2015.04.038","article-title":"Comparison of the effectiveness of four antiepileptic drugs in the treatment of status epilepticus according to four different efficacy criteria","volume":"49","author":"Redecker","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107139_bb0195","series-title":"Zonegran \u2013 ANNEX I \u2013 summary of products characteristics","author":"European Medicines Agency","year":"2019"},{"key":"10.1016\/j.yebeh.2020.107139_bb0200","doi-asserted-by":"crossref","first-page":"106370","DOI":"10.1016\/j.yebeh.2019.06.014","article-title":"Tumor-associated status epilepticus in patients with glioma: clinical characteristics and outcomes","volume":"101","author":"Giovannini","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107139_bb0205","doi-asserted-by":"crossref","first-page":"106288","DOI":"10.1016\/j.yebeh.2019.04.041","article-title":"Management of prolonged epileptic seizures and status epilepticus in palliative care patients","volume":"101","author":"K\u00e4lvi\u00e4inen","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107139_bb0210","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2377-14-152","article-title":"Prognosis and therapy of tumor-related versus non-tumor-related status epilepticus: a systematic review and meta-analysis","volume":"14","author":"Arik","year":"2014","journal-title":"BMC Neurol"},{"key":"10.1016\/j.yebeh.2020.107139_bb0215","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/epi.13716","article-title":"Lacosamide in status epilepticus: systematic review of current evidence","volume":"58","author":"Strzelczyk","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107139_bb0220","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/ane.12174","article-title":"Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus","volume":"129","author":"Kellinghaus","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2020.107139_bb0225","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.yebeh.2017.03.028","article-title":"Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals","volume":"70","author":"Strzelczyk","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107139_bb0230","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/epi.16094","article-title":"Use of intravenous brivaracetam in status epilepticus: a multicenter registry","volume":"60","author":"Santamarina","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107139_bb0235","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eplepsyres.2018.12.001","article-title":"Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma levels and clinical response","volume":"149","author":"Aicua-Rapun","year":"2019","journal-title":"Epilepsy Res"},{"issue":"Suppl. 2","key":"10.1016\/j.yebeh.2020.107139_bb0240","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/epi.14486","article-title":"Intravenous brivaracetam in status epilepticus: a retrospective single-center study","volume":"59","author":"Kalss","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107139_bb0245","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.seizure.2019.07.003","article-title":"Risks and management of antiepileptic drug induced skin reactions in the adult out-patient setting","volume":"72","author":"Fowler","year":"2019","journal-title":"Seizure"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020303188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020303188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:32:03Z","timestamp":1761503523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505020303188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":49,"alternative-id":["S1525505020303188"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107139","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of status epilepticus with zonisamide: A multicenter cohort study of 34 patients and review of literature","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107139"}}